

DETECTION OF *SUTTERELLA* IN THE STOOL OF EGYPTIAN CHILDREN WITH AUTISM SPECTRUM DISORDERS

ABSTRACT (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

Background: Autism spectrum disorder (ASD) is a multifaceted group of neurodevelopmental disorders. Gastrointestinal problems are commonly reported in children with autism and may correlate with autism severity. A recent study reported that *Sutterella* species were frequently found in individuals with autism that was not found in controls.

Aim: The aim of the present study was to study the role of *Sutterella* species in Egyptian children with Autism Spectrum Disorders (ASDs).

Methods: Thirty children diagnosed with ASDs according to DMS-V criteria aged between 2.5-8 years old together with a cross matching control group of 30 healthy neurotypical children were included in the present study. Gastrointestinal symptoms were assessed with a modified six-item GI Severity Index (6-GSI) questionnaire. Stool specimens were taken for detection of *Sutterella* by the Conventional PCR using primers that amplify a 260-bp region spanning the variable regions from V6 to V8 of the 16S rRNA gene.

Results: *Sutterella* species was detected in 24 cases out of 30 ASD patients (80%), and in 11 (36.7%) out of the control cases. There was no significant correlation between the presence of *Sutterella* and the severity of ASD or GSI.

Conclusion: These results indicate that *Sutterella* species may have a role in ASD.

Keywords: Autism; *Sutterella*; PCR; 16S rRNA; ASD; stool

1. INTRODUCTION

Autism spectrum disorder (ASD) is a multifaceted group of neurodevelopmental disorders. After the publication in May 2013 of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), autism disorders were merged into one umbrella for diagnosis of ASD.¹ Previously, they were recognized as distinct subtypes, including the severe form of autistic disorder, childhood disintegrative disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS) and the milder form of Asperger syndrome. Delay in language and age of onset are not emphasized in DSM-V diagnostic criteria. [1]

Since autism was first explained in the 1940s, it has been looked upon as a rare disorder, occurring at a rate of 4-5 every 10,000 children.[2] Since then, however, incidences have been on the rise. Now autism is generally accepted to be a grand challenge to global mental health. [3,4]. The prevalence of ASD among children with developmental disorders reached 33.6 % and 11.5% in Egypt and Tunisia respectively. [5]

The gastrointestinal microbiota (GM) is known to play an essential role in physiological homeostasis in the intestine and periphery, including brain development and behavior [6,7]. For the last several years several clinical studies have shown altered gut microbiota composition in patients with neurodevelopmental disorders [8].

During the recent years, a substantial amount of new data has underlined the importance of the gut as a triggering place for autism [9]. In children with ASD, the presence of gastrointestinal (GI) dysfunction is often associated with increased irritability, tantrums, aggressive behaviour, and sleep disturbances. Moreover, modulating gut bacteria with short-term antibiotic treatment can lead to temporary improvement in behavioral symptoms in some individuals with ASD. [10,11].

Members of the genus *Sutterella* were first described in 1996 by Wexler et al. They are anaerobic or microaerophilic, short rods gram-negative, non-spore-forming bacteria from the family of *Sutterellaceae* which belongs to the class of *Betaproteobacteria* of the order *Burkholderiales* and were isolated from human faeces. [12,13]

There is evidence that *Sutterella* occurs in human faeces as a common member of the human indigenous microflora [14]. Studies have, however, linked *Sutterella* to the pathogenesis of GI disturbances in children with autism [15], though the studies are not sufficient to ensure that there is a definite relationship.

The aim of the present study was to detect the association between *Sutterella* species in stool and Autism Spectrum Disorders (ASDs).

2. MATERIAL AND METHODS / EXPERIMENTAL DETAILS / METHODOLOGY

Subjects. Thirty autistic children with and without gastrointestinal symptoms, who presented to the autism clinic of Alexandria University Children's Hospital were enrolled in our study. These children were diagnosed with ASDs according to DMS-V criteria [1] and CARS (Childhood Autism Rating Scale) was used to assess severity of autism.[16].

A cross matching control group of 30 healthy neurotypical children of similar age and sex was also included.

After receiving informed consent from the parent, a clinical history for each case and stool sample were obtained.

In addition gastrointestinal symptoms were assessed in cases with a modified six-item GI Severity Index (6-GSI) questionnaire. Specifically, it included only six items (constipation, diarrhea, stool consistency, stool smell, flatulence, and abdominal pain). The absence of a symptom was 0, its presence ranged from 1 to 2 depending on the severity of the symptom, thus the score includes the number of symptoms and their severity. [17]

Specimen collection, preservation and transport

Stool specimens were collected by parents, kept in the freezer upon defecation at home, and within the same day delivered to our laboratory frozen, where aliquots of each specimen were frozen at -80 °C until DNA extraction in the same week.

Polymerase Chain Reaction Assay.

DNA was extracted from 150 mg stool samples using ISOLATE Fecal DNA Kit (Bioline, UK) according to the manufacturers' instructions. In brief, fecal samples were added directly to a bashing beads lysis tube and they were rapidly lysed by bead beating in a vortex, without the use of organic

denaturants or proteinases. The DNA was then bound, isolated and purified using spin columns. The resulting DNA extracts were stored at -70 °C until PCR assessment.

Conventional PCR for detection of *Sutterella* was carried out using primers SuttFor (5'-CGCGAAAAACCTTACCTAGCC-3') and SuttRev (5'-GACGTGTGAGGCCCTAGCC-3'), that amplify a 260-bp region spanning the variable regions from V6 to V8 of the 16S rRNA gene. [15]

Reaction was performed in a final volume of 25 µl of PCR mixture containing 0.8 µM of each primer (Metabion International AG, Germany), 2X MyTaq™ Red PCR Mix (Bioline, UK), and 3 µl of template DNA. DNA amplification was carried out with a thermal cycler (Genius Techne, England) as follow: Denaturation at 95 °C for 15 minutes in the first cycle, followed by annealing for 1 minute at 60 °C, extension for 1 minutes at 72 °C, and denaturation for 1 minute at 94 °C for a total of 30 PCR cycles. The extension for the last cycle was increased to 5 minutes to ensure complete extension of the amplified fragment. The amplified product was detected by electrophoresis on a 1.5% agarose gel stained with ethidium bromide. [15]

Statistical analysis of the data

The statistical significance of observed differences was evaluated using independent t test for normally distributed continuous variables and the Mann-Whitney *U* test for non-normally distributed continuous variables and the χ^2 or Fisher's exact test for categorical variables, where appropriate. *P* < 0.05 was considered statistically significant. Data were analyzed with IBM SPSS version 23.0.

3. RESULTS AND DISCUSSION

3.1 Results

Out of the 30 patients, 23 were males and 7 were females with male to female ratio of 3.3:1. The mean age was 4.4 ± 1.5 and their age ranged from 2.5-8 years. Out of the 30 control cases examined there were 21 males and 9 females, with male to female ratio of 2.3:1. The mean age $\pm$ SD was 4.3 ± 1.9 , and their age ranged from 2-8 years. According to Childhood Autism Rating Scale (CARS), all the ASD cases were mild to moderate with mean CARS 29.8 ± 3.55 . 15 out of 30 (50%) of ASD patients were mild while the other 15 were moderate ASD. For the male patients 11 out of 23 (47.8%) and 12 out of 23 (52.2%) were mild and moderate ASD respectively. For the female patients 4 out of 7 (57.1%) and 3 out of 7 (42.9%) were mild and moderate ASD respectively, (statistically nonsignificant, *P* value 0.204).

In this study, GI disturbances were scored using a modified version of standardized GI-Severity Index (GSI), which takes into account constipation, diarrhea, stool consistency, stool smell, flatulence, and abdominal pain. The mean of GSI was 3.5 ± 1.8 . Out of the 30 ASD cases, 27 (90%) have at least one GI symptom at the time of examination. Only 3 cases (10%) did not have any symptom. As regards bowel movement, out of the 30 ASD cases at the time of 15(50%), 4 (13.3%) and 11 (36.7%) had constipation, diarrhea, and no constipation/diarrhea respectively. For other symptom, 22 (73.3%), 14 (46.7%), 7 (23.3%) and 2 (6.7%) had abnormal stool smell, flatulence, abdominal pain, and unformed stool respectively. There was negative correlation between the GSI AND CARS of the ASD cases (-0.0286) and a significant relation at *P* value <0.001. None of the control cases had GI disturbances (Table I).

Table (I): Characteristics of ASD Patients

Characteristics	No (%)
-----------------	--------

Mean age $\pm$ SD	4.5 $\pm$ 1.6
Age range	2.5-8
Male: Female ratio	3.3:1
CARS	29.8 $\pm$ 3.55
GSI $\pm$ SD	3.5 $\pm$ 1.8
GI Symptoms	27 (90%)
Abnormal stool smell	17 (70.8%)
Constipation	13 (54.2%)
Flatulence	13 (54.2%)
No constipation/diarrhea	7 (29.2%)
Abdominal pain	5 (20.8%)
Diarrhea	4 (16.7%)
Unformed stool	2 (8.3%)

110

111 By comparing the GSI and the CARS of ASD cases, the mean GSI for mild was 3.53 $\pm$ 1.7, while that for
112 the moderate was 3.47 $\pm$ 2.1 (statistically non significant, P value 1.96).

113 *Sutterella* was detected in 24 out of 30 ASD cases (80%), and in the 11 out of 30 (36.7%) in control cases
114 and this is statistically significant with p=0.001 (Table II).

115 **Table II: Comparison between *Sutterella* Positive ASD and Control Cases**

	ASD	CONTROL	P value
Total Cases	24 (80%)	11 (36.7%)	0.001
Age			
Mean age $\pm$ SD	4.5 $\pm$ 1.6	4.3 $\pm$ 2.2	0.900
Age range	2.5-8	2-8	
Gender			
Male	19 (79.2%)	8 (72.7%)	0.673
Female	5 (20.8%)	3 (27.3%)	
CARS			

Mean ± SD	29.8±3.55	-	
GI Symptoms			
GSI Mean ± SD	3.5±1.8	0	0.116
GSI Range	0-6	0	
Constipation	13 (54.2%)	0	0.002
Diarrhea	4 (16.7%)	0	0.150
No constipation/diarrhea	7 (29.2%)	11 (100%)	0.00009
Abnormal stool smell	17 (70.8%)	0	0.00009
Flatulence	13 (54.2%)	0	0.002
Abdominal pain	5 (20.8%)	0	0.102
Unformed stool	2 (8.3%)	0	0.324

116 As shown in table (III), *Sutterella* was detected in 24 ASD cases with mean age ± SD 4.5±1.6, while the
 117 remaining 6 cases (20%) with mean age ± SD 4.1 ± 0.5 were negative (statistically nonsignificant t= 0.2,
 118 P value 0.854) (Figure I). Among the male patients, 19 out of 23 cases (82.6%) were positive for
 119 *Sutterella*. For the female patients, 5 out of 7 cases (71.4%) were positive. The difference between the
 120 percentage of male and female positive cases is statistically nonsignificant (P value 0.517). The CARS of
 121 the positive cases was 29.8±3.55 while that of the negative cases was 31.66±3.33 (statistically non
 122 significant, P value 0.489).

123 **Table III: Characteristics of *Sutterella* Positive and Negative ASD Patients**

	<i>Sutterella</i> Positive	<i>Sutterella</i> Negative	P value
Total Cases	24 (80%)	6 (20%)	
Age			
Mean age ± SD	4.5±1.6	4.1 ± 0.5	0.556
Age range	2.5-8	3.5-5	
Gender			
Male	19 (79.2%)	4 (66.7%)	0.517
Female	5 (20.8%)	2 (33.3%)	
CARS			
Mean ± SD	29.8±3.55	31.66±3.33	0.489

GI Symptoms			
GSI Mean ± SD	3.5±1.8	2.2±2.2	0.116
GSI Range	0-6	0-6	0.361
Constipation	13 (54.2%)	2 (33.3%)	0.324
Diarrhea	4 (16.7%)	0 (0%)	0.088
No constipation/diarrhea	7 (29.2%)	4 (66.7%)	0.536
Abnormal stool smell	17 (70.8%)	5 (83.3%)	0.361
Flatulence	13 (54.2%)	1 (16.7%)	0.099
Abdominal pain	5 (20.8%)	2 (33.3%)	0.517
Unformed stool	2 (8.3%)	0 (0%)	0.464

124

125 The GSI of the positive cases was 3.7±1.8 while that of the negative cases is 2.8±2.0 (statistically non
126 significant, P value 0.313).

127 As shown in table (III), out of the 24 *Sutterella* positive ASD cases 13 (54.2%), 4 (16.7%) and 7 (29.2%)
128 had constipation, diarrhea, and no constipation/diarrhea respectively. For other symptoms, 17 (70.8%),
129 13 (54.2%), 5 (20.8%) and 2 (8.3%) had abnormal stool smell, flatulence, abdominal pain, and unformed
130 stool respectively. For the 6 *Sutterella* negative ASD cases 2 (33.3%), 0 (0%) and 4 (66.7%) had
131 constipation, diarrhea, and no constipation/diarrhea respectively. For other symptoms, 5 (83.3%), 1
132 (16.7%), 2 (33.3%) and 0 (0%) had abnormal stool smell, flatulence, abdominal pain, and unformed stool
133 respectively. (statistically nonsignificant).




Figure (I): Agarose gel electrophoresis for detection of *Sutterella* PCR product (v6-v8), lane M: 100 bp ladder, lanes 1-11: Positive cases showing PCR product (260 bp).

As shown in table (II), *Sutterella* was detected in 11 cases of the control group. The mean age $\pm$ SD of the positive cases was 4.3 ± 2.2 , while that of the negative cases was 4.3 ± 1.7 (statistically nonsignificant $t=0.11$, P value 0.897). Among the male patients there were 8 out of 21 cases were positive for *Sutterella* (38.1%). For the female patients, 3 out of 9 cases were positive (33.3%). The difference between the percentage of male and female cases is statistically nonsignificant (P value 0.046).

Table (II) shows the comparison between the *Sutterella* positive ASD and neurotypical control cases as regards age, gender and GI symptoms (statistically nonsignificant, P value 0.771, 0.842, and 0.313 respectively).

3.2 Discussion

Autism spectrum disorders are a diverse group of disorders caused by a complex interplay between genetic and environmental components. [18,19], There is some preliminary evidence suggesting that exposure to viral or bacterial pathogens may play a role in triggering the disorder in a small subgroup of individuals with autism. [20,21].

Of the many medical comorbidities associated with ASD, gastrointestinal (GI) distress has gained significant attention because of its reported prevalence and association with symptom severity.^{22,23} The

propensity for associated GI issues in many ASD children has led some researchers to hypothesize a gut microbial involvement in disease [24,25].

Whether microbiota changes can contribute to the development or progression of autism symptoms is unknown. Attempts have been made to define and isolate the possible, specific intestinal bacterial species that may play some role in this disorder. Recently, the focus has been on the presence of the genus *Sutterella*. [15,25].

The present study was conducted on 30 ASD and 30 neurotypical control children. The ASD patients were 23 males and 7 females with a ratio 3.3:1, their age range 2.5-8 years and mean age 4.4 ± 1.5 . GI disturbances have been apparent in 90% of our patients, in the form of abnormal stool smell (73.3%), constipation (50%), flatulence (46.7%), abdominal pain (23.3%), diarrhea (13.3%), and unformed stool (6.7%).

By using CARS for the assessment of the severity of autism, all of ASD patients were mild to moderate. There was no significant difference between male and female patients as regards the severity of autism. Also there was no significant difference between the GSI and the CARS of ASD cases, the GSI for the mild was 5.3, while for the moderate was 5.2.

By PCR *Sutterella* DNA has been detected in 80% of ASD cases, and 36.7% of control cases. There was no significant correlation between the presence of *Sutterella* and the severity of ASD or GSI.

Regarding the sex distribution, the present study agrees with studies reporting that autism is more common in boys than girls while it disagrees as regards autism is more severe in girls than boys, but this may be explained by the small sample size of the females to allow for comparisons in our study [4,26].

As regards the GI disturbances in the present study our results agree with many studies reporting GI disturbances as a common comorbidity in ASD patients as the case with 90% of our ASD patients. However, it disagrees with the positive correlation of GSI with ASD symptom severity²⁷⁻³⁰. Comparison between studies is quite difficult due to the fact that different methodologies for assessment of ASD severity and GI symptoms severity. Moreover, our study may not be comparable due to the small sample size and limited diversity of cases, all are mild to moderate.

As regards *Sutterella*, our results demonstrated that *Sutterella* is detected much more in the feces of children with ASD relative to the controls. This confirms the findings of Williams et al [15], who were the first to develop *Sutterella*-specific PCR assays for detecting *Sutterella* species in biological and environmental samples, used in our study. They demonstrated increased levels of *Sutterella* in intestinal biopsy samples from 12 of 23 (52%) ASD children with GI disturbance and its absence in the 9 control children with GI symptoms only, further emphasizing that such species might play an important role in the microbiota gut-brain axis. [15].

However, a study done by Kang et al [31], have found no increase in *Sutterella* in their ASD cases compared to the controls. The association of *Sutterella* with ASD was reported in other studies that found differences in *Sutterella* detected from mucosal-biopsies as compared to those fecal samples, which may explain the different prevalences of *Sutterella* between various studies. [15].

In contrast Wang et al [25] observed higher levels of *Sutterella* and *Ruminococcus* spp. in stool samples of individuals with ASD compared to controls. Their results thus indicate that fecal samples used in molecular techniques are sufficient for the detection and quantification of *Sutterella* in the human gut, including children with ASD.

4. CONCLUSION

The role that *Sutterellae* play in ASD is not yet apparent but they may relate to bigger scale shifts in the microbial populations as a consequence of the condition. The outcome of this study offer strong grounds to carry out further investigations to ascertain its possible role - if ever – in the pathogenesis of ASD patients.

Disclaimer

Some part of this manuscript was previously presented and published in the following conference.
Conference name: American Society for Microbiology 115th General Meeting
Dates: May 30–June 2, 2015
Location: New Orleans, Louisiana

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: 2013.
2. Kanner L. Autistic disturbances of affective contact.. In: Acta paedopsychiatrica. 1943. p. 217–50.
3. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005;162(6):1133–41.
4. CDC Report MW. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014;63(2):1–21.
5. Hussein H, Taha GRA. Autism spectrum disorders: a review of the literature from Arab countries. Middle East Curr Psychiatry 2013;20(3):106–16.
6. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7(7):688–93.
7. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. PNAS 2011;108(7):3047–52.
8. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009;6(5):306–14.
9. Midtvedt T. The gut: a triggering place for autism--possibilities and challenges. Microb Ecol Health Dis 2012;23.
10. Critchfield JW, Van Hemert S, Ash M, Mulder L, Ashwood P. The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011;2011:161358.
11. Frye RE, Slattery J, MacFabe DF, Allen-Vercoe E, Parker W, Rodakis J et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis 2015;26.
12. Wexler HM. The Proteobacteria Part 3. Genus VIII. Sutterella. In: Brenner DJ, Krieg NR SJ, editor. Bergey's Manual of Systematic Bacteriology - Vol 2. New York, NY: Springer-Verlag; 2005.
13. Morotomi M, Nagai F, Watanabe Y. Parasutterella secunda sp. nov., isolated from human faeces and proposal of Sutterellaceae fam. nov. in the order Burkholderiales. Int J Syst Evol Microbiol 2010;61(3):637–43.
14. Hong P-Y, Croix JA, Greenberg E, Gaskins HR, Mackie RI. Pyrosequencing-based analysis of the mucosal microbiota in healthy individuals reveals ubiquitous bacterial groups and micro-heterogeneity. PLoS One 2011;6(9):e25042.
15. Williams BL, Hornig M, Parekh T, Ian Lipkin W. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 2012;3(1):1–11.
16. Ozonoff S, Williams BJ, Landa R. Parental report of the early development of children with regressive autism The delays-plus-regression phenotype. Autism 2005;9(5):461–86.
17. Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord 2006;36(8):1053–64.

18. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. *Genet Med* 2008;10(1):4–12.
19. Miles JH. Autism spectrum disorders—a genetics review. *Genet Med* 2011;13(4):278–94.
20. Benach JL, Li E, McGovern MM. A microbial association with Autism. *MBio* 2012;3(1):1–3.
21. Sweeten TL, Posey DJ, McDougale CJ. Brief report: autistic disorder in three children with cytomegalovirus infection. *J Autism Dev Disord* 2004;34(5):583–6.
22. Buie T, Campbell DB, Fuchs GJ, Furuta GT, Levy J, Vandewater J et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. In: *Pediatrics*. 2010. p. S1–18.
23. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. *BMC Gastroenterol* 2011;11:22.
24. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD et al. Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe* 2010;16(4):444–53.
25. Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Increased abundance of *Sutterella* spp. and *Ruminococcus torques* in feces of children with autism spectrum disorder. *Mol Autism* 2013;4(1):42.
26. Hartley SL, Sikora DM. Sex differences in autism spectrum disorder: An examination of developmental functioning, autistic symptoms, and coexisting behavior problems in toddlers. *J Autism Dev Disord* 2009;39(12):1715–22.
27. Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ. Incidence of gastrointestinal symptoms in children with autism: a population-based study. *Pediatrics* 2009;124(2):680–6.
28. Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. *J Dev Behav Pediatr* 2011;32(5):351–60.
29. Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. *Autism Res* 2012;5(2):101–8.
30. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. *J Autism Dev Disord* 2014;44(5):1117–27.
31. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB et al. Reduced Incidence of *Prevotella* and Other Fermenters in Intestinal Microflora of Autistic Children. *PLoS One* 2013;8(7):e68322.